DNA Repair Biomarkers Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer

被引:45
|
作者
Alexander, Brian M. [1 ]
Wang, Xiao Zhe [2 ,3 ]
Niemierko, Andrzej
Weaver, David T. [2 ,3 ]
Mak, Raymond H.
Roof, Kevin S. [6 ]
Fidias, Panagiotis [4 ]
Wain, John [5 ]
Choi, Noah C.
机构
[1] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA
[2] On Q Ity Inc, Waltham, MA USA
[3] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[5] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA
[6] SE Radiat Oncol, Charlotte, NC USA
关键词
Biomarkers; Chemoradiotherapy; DNA repair; Esophageal cancer; SQUAMOUS-CELL CARCINOMA; POOR-PROGNOSIS; CHEMOTHERAPY; EXPRESSION; CHEMORADIATION; DEFICIENCY; CISPLATIN; BENEFITS; HMLH1;
D O I
10.1016/j.ijrobp.2011.05.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The addition of neoadjuvant chemoradiotherapy prior to surgical resection for esophageal cancer has improved clinical outcomes in some trials. Pathologic complete response (pCR) following neoadjuvant therapy is associated with better clinical outcome in these patients, but only 22% to 40% of patients achieve pCR. Because both chemotherapy and radiotherapy act by inducing DNA damage, we analyzed proteins selected from multiple DNA repair pathways, using quantitative immunohistochemistry coupled with a digital pathology platform, as possible biomarkers of treatment response and clinical outcome. Methods and Materials: We identified 79 patients diagnosed with esophageal cancer between October 1994 and September 2002, with biopsy tissue available, who underwent neoadjuvant chemoradiotherapy prior to surgery at the Massachusetts General Hospital and used their archived, formalin-fixed, paraffin-embedded biopsy samples to create tissue microarrays (TMA). TMA sections were stained using antibodies against proteins in various DNA repair pathways including XPF, FANCD2, PAR, MLH1, PARP1, and phosphorylated MAPKAP kinase 2 (pMK2). Stained TMA slides were evaluated using machine-based image analysis, and scoring incorporated both the intensity and the quantity of positive tumor nuclei. Biomarker scores and clinical data were assessed for correlations with clinical outcome. Results: Higher scores for MLH1 (p = 0.018) and lower scores for FANCD2 (p = 0.037) were associated with pathologic response to neoadjuvant chemoradiation on multivariable analysis. Staining of MLH1, PARP1, XPF, and PAR was associated with recurrence-free survival, and staining of PARP1 and FANCD2 was associated with overall survival on multivariable analysis. Conclusions: DNA repair proteins analyzed by immunohistochemistry may be useful as predictive markers for response to neoadjuvant chemoradiotherapy in patients with esophageal cancer. These results are hypothesis generating and need confirmation in an independent data set. (C) 2012 Elsevier Inc.
引用
收藏
页码:164 / 171
页数:8
相关论文
共 50 条
  • [11] Neoadjuvant chemoradiotherapy for esophageal cancer - Is it worthwhile?
    Tamim, WZ
    Davidson, RS
    Quinlan, RM
    O'Shea, MA
    Orr, RK
    Swanson, RS
    ARCHIVES OF SURGERY, 1998, 133 (07) : 722 - 726
  • [12] A Machine Learning Model with Radiomics Based on PET Images to Predict Pathological Response by Neoadjuvant Chemoradiotherapy for Esophageal Cancer
    Murakami, Y.
    Kawahara, D.
    Imano, N.
    Takahashi, I.
    Takeuchi, Y.
    Nishibuchi, I.
    Kimura, T.
    Nagata, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E622 - E622
  • [13] Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer
    Soror, Tamer
    Kho, Gerlinda
    Zhao, Kuai-Le
    Ismail, Mahmoud
    Badakhshi, Harlin
    JOURNAL OF THORACIC DISEASE, 2018, 10 (07) : 4069 - 4076
  • [14] Can pretreatment blood biomarkers predict pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer?
    Morais, Marina
    Fonseca, Telma
    Machado-Neves, Raquel
    Honavar, Mrinalini
    Coelho, Ana Rita
    Lopes, Joanne
    Barbosa, Elisabete
    Guerreiro, Emanuel
    Carneiro, Silvestre
    FUTURE ONCOLOGY, 2021, 17 (35) : 4947 - 4957
  • [15] Inflammatory markers to predict neoadjuvant chemoradiotherapy response in rectal cancer patients
    Alkis, H.
    Ozden, G.
    Baskan, Z.
    Kilic, M. Bagci
    Gunduz, H. K.
    Kornienko, A.
    Devran, B. Z.
    Adli, M.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S687 - S687
  • [16] Esophageal cancer: improved prognosis with neoadjuvant chemoradiotherapy
    Knippen, Stefan
    Duma, Marciana-Nona
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (01) : 86 - 88
  • [17] Anastomotic leak and neoadjuvant chemoradiotherapy in esophageal cancer
    Shridhar, Ravi
    Takahashi, Caitlin
    Huston, Jamie
    Doepker, Matthew P.
    Meredith, Kenneth L.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (05) : 894 - 902
  • [18] The use of neoadjuvant chemoradiotherapy for resectable esophageal cancer
    Chidel, M
    Rice, TW
    Kupelian, PA
    Adelstein, D
    Becker, M
    RADIOLOGY, 1997, 205 : 1082 - 1082
  • [19] Pre-treatment complement system serum protein levels predict pathological response to neoadjuvant chemoradiotherapy for esophageal cancer
    Maher, Stephen G.
    McDowell, Dermot T.
    Murphy, Sinead A.
    Collins, Ben C.
    Muldoon, Clan
    Gallagher, William M.
    Reynolds, John V.
    CANCER RESEARCH, 2011, 71
  • [20] Neoadjuvant Chemoradiotherapy in Esophageal Cancer: Is It Still the Question?
    Pereira, Bruno
    Gourgou-Bourgade, Sophie
    Azria, David
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (31) : 5133 - 5134